Sana Biotechnology Stock Performance
| SANA Stock | USD 2.78 0.23 9.02% |
The entity has a beta of 1.62, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sana Biotechnology will likely underperform. At this point, Sana Biotechnology has a negative expected return of -0.98%. Please make sure to validate Sana Biotechnology's accumulation distribution, and the relationship between the potential upside and day median price , to decide if Sana Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sana Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 9.02 | Five Day Return 4.91 | Year To Date Return (33.81) | Ten Year Return (92.08) | All Time Return (92.08) |
1 | Disposition of 150000 shares by Richard Mulligan of Sana Biotechnology at 4.0838 subject to Rule 16b-3 | 09/24/2024 |
2 | Disposition of 150000 shares by Richard Mulligan of Sana Biotechnology at 3.8878 subject to Rule 16b-3 | 09/25/2024 |
3 | Insider Trading | 10/04/2024 |
4 | Acquisition by Bishop Hans Edgar of 5938 shares of Sana Biotechnology subject to Rule 16b-3 | 10/07/2024 |
5 | Sana Biotechnology, Inc. Shares Sold by Marshall Wace LLP - MarketBeat | 10/08/2024 |
6 | Disposition of 345069 shares by Flagship Pioneering Inc. of Sana Biotechnology subject to Rule 16b-3 | 10/11/2024 |
7 | Why Sana Biotechnology, Inc. is the Penny Stock with the Biggest Upside Potential According to Analysts | 10/16/2024 |
8 | Sana Biotechnology Stock Price Down 6.6 percent - Heres Why - MarketBeat | 10/29/2024 |
9 | Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept ... | 11/04/2024 |
10 | Vanguard Group Incs Strategic Acquisition of Sana Biotechnology Inc Shares | 11/05/2024 |
11 | Down -24.69 percent in 4 Weeks, Heres Why Sana Looks Ripe for a Turnaround | 11/11/2024 |
12 | Shareholder Rights Advocates at Levi Korsinsky Investigate Sana Biotechnology, Inc. Regarding Possible Securities Fraud Violations | 11/12/2024 |
13 | FMR LLCs Strategic Acquisition of Sana Biotechnology Inc Shares | 11/13/2024 |
14 | Levi Korsinsky Announces an Investigation on Behalf of Sana Biotechnology, Inc. Shareholders Who May Have Been Affected by Fraud | 11/18/2024 |
15 | Acquisition by Williams Douglas E of 67083 shares of Sana Biotechnology subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 187.3 M |
Sana |
Sana Biotechnology Relative Risk vs. Return Landscape
If you would invest 560.00 in Sana Biotechnology on September 2, 2024 and sell it today you would lose (282.00) from holding Sana Biotechnology or give up 50.36% of portfolio value over 90 days. Sana Biotechnology is currently does not generate positive expected returns and assumes 4.7207% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Sana, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sana Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sana Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sana Biotechnology, and traders can use it to determine the average amount a Sana Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2075
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SANA |
Estimated Market Risk
| 4.72 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sana Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sana Biotechnology by adding Sana Biotechnology to a well-diversified portfolio.
Sana Biotechnology Fundamentals Growth
Sana Stock prices reflect investors' perceptions of the future prospects and financial health of Sana Biotechnology, and Sana Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sana Stock performance.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 517.76 M | ||||
| Shares Outstanding | 223.27 M | ||||
| Price To Book | 2.12 X | ||||
| EBITDA | (252.39 M) | ||||
| Net Income | (283.25 M) | ||||
| Cash And Equivalents | 484.8 M | ||||
| Cash Per Share | 2.57 X | ||||
| Total Debt | 104.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 5.09 X | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (253.58 M) | ||||
| Earnings Per Share | (1.40) X | ||||
| Market Capitalization | 620.69 M | ||||
| Total Asset | 565.3 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 149.03 M | ||||
About Sana Biotechnology Performance
By analyzing Sana Biotechnology's fundamental ratios, stakeholders can gain valuable insights into Sana Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sana Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sana Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.81) | |
| Return On Capital Employed | (0.65) | (0.69) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.99) | (0.94) |
Things to note about Sana Biotechnology performance evaluation
Checking the ongoing alerts about Sana Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sana Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sana Biotechnology generated a negative expected return over the last 90 days | |
| Sana Biotechnology has high historical volatility and very poor performance | |
| Sana Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (283.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sana Biotechnology currently holds about 484.8 M in cash with (253.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.57. | |
| Sana Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Williams Douglas E of 67083 shares of Sana Biotechnology subject to Rule 16b-3 |
- Analyzing Sana Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sana Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Sana Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sana Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sana Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sana Biotechnology's stock. These opinions can provide insight into Sana Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sana Stock analysis
When running Sana Biotechnology's price analysis, check to measure Sana Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sana Biotechnology is operating at the current time. Most of Sana Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sana Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sana Biotechnology's price. Additionally, you may evaluate how the addition of Sana Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |